RESULTS OF STAGED ENDOVASCULAR MYOCARDIAL REVASCULARISATION IN PATIENTS TREATED FOR ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION AND MULTIVESSEL DISEASE
https://doi.org/10.25207/1608-6228-2019-26-3-00-25-32
Abstract
Aim. To evaluate the results of complete functional endovascular myocardial revascularisation which is performed early after stenting the culprit artery (within 90 days) with third-generation sirolimus-eluting stents in patients treated for acute coronary syndrome (ACS) with ST-segment elevation and multivessel disease.
Materials and methods. We analysed the results of a 2-year follow-up treatment period of patients suffering from ACS with ST-segment elevation and multivessel disease who had undergone urgent stenting of culprit artery. Within 90 days after stenting, a complete functional endovascular myocardial revascularisation was performed using third-generation sirolimus-eluting stents. The efficacy and safety of the procedure was evaluated according to the non-inferiority criteria in comparison with the literature data on myocardial revascularisation by coronary artery bypass surgery.
Results. In the course of follow-up treatment, 1 lethal myocardial infarction (after 18 months from complete revascularisation) and 2 non-lethal myocardial infarctions were registered. The symptoms of angina returned in 7 patients, 6 of whom had undergone unplanned re-revascularisation within 6 to 12 months following complete revascularisation. The MACCE rate was 0.143 [95% confidence interval: 0.0770; 0.2497].
Conclusion. In patients having ACS with ST-segment elevation and multivessel disease, endovascular myocardial revascularisation performed early after stenting the culprit artery is equivalent to coronary artery bypass surgery in terms of cardiovascular mortality rates, as well as incidence of non-fatal cardiovascular events. However, such an approach underperforms compared to coronary artery bypass surgery in terms of a composite endpoint of MACCE and the number of required re-interventions.
About the Authors
Alexander V. Bocharov
Kostroma Regional Clinical Hospital named after E.I. Korolev
Russian Federation
Russian Federation
Cand. Sci. (Med.), Head of the Department of X-ray Surgical Methods for Diagnostics and Treatment,
Prospekt Mira, 114, Kostroma, 156013;
tel.: -+7 (953) 663-68-11; Tesny pereulok, 21, Kostroma, 156002
Leonid V. Popov
National Medical and Surgical Centre named after N.I. Pirogov, Ministry of Healthcare of the Russian Federation
Russian Federation
Russian Federation
Dr. Sci. (Med.), Prof., Head of the Department for Cardiac Surgery,
Nizhnyaya Pervomayskaya str.,70, Moscow, 105203
References
1. Dziewierz A., Siudak Z., Rakowski T., Zasada W., Dubiel J.S., Dudek D. Impact of multivessel coronary artery disease and noninfarct-related artery revascularization on outcome of patients with ST-elevation myocardial infarction transferred for primary percutaneous coronary intervention (from the EUROTRANSFER Registry). Am.J. Cardiol. 2010; 106(3): 342–347. DOI: 10.1016/j.amjcard.2010.03.029
2. Topol E.J., Teirstein P.S. Textbook of interventional cardiology. 7thed. Elsevier; 2017. 1104 р.
3. Babunashvili A.M., Ivanov V.A. Khronicheskie okklyuzii koronarnykh arterii: anatomiya, patofziologiya, endovaskulyarnoe lechenie. [Chronic coronary artery occlusion: anatomy, pathophysiology, endovascular treatment]. Мoscow: АСВ; 2012. 629 р. (In Russ.).
4. Wald D.S., Morris J.K., Wald N.J., Chase A.J., Edwards R.J., Hughes L.O., Berry C., Oldroyd K.G., PRAMI Investigators. Randomized trial of preventive angioplasty in myocardial infarction. N. Engl.J. Med. 2013; 369(12): 1115–1123. DOI: 10.1056/nejmoa1305520
5. Gershlick A.H., Khan J.N., Kelly D.J., Greenwood J.P., Sasikaran T., Curzen N., Blackman D.J., Dalby M., Fairbrother K.L., Banya W., Wang D., Flather M., Hetherington S.L., Kelion A.D., Talwar S., Gunning M., Hall R., Swanton H., McCann G.P. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J. Am. Coll. Cardiol. 2015; 65(10): 963–972. DOI: 10.1016/j.jacc.2014.12.038
6. Engstrom T., Kelbaek H., Helqvist S., Hofsten D.E., Klovgaard L., Holmvang L., Jorgensen E., Pedersen F., Saunamaki K., Clemmensen P., De Backer O., Ravkilde J., Tilsted H.H., Villadsen A.B., Aaroe J., Jensen S.E., Raungaard B., Kober L., DANAMI-PRIMULTI Investigators. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015; 386(9994): 665–671. DOI: 10.1016/s0140-6736(15)60648-1
7. Smits P.C., Abdel-Wahab M., Neumann F.J., Boxma-de Klerk B.M., Lunde K., Schotborgh C.E., Piroth Z., Horak D., Wlodarczak A., Ong P.J., Hambrecht R., Angeras O., Richardt G., Omerovic E., Compare-Acute Investigators. Fractional flow reserve-guided multivessel angioplasty in myocardial infarction. N. Engl.J. Med. 2017; 376(13): 1234–1244. DOI: 10.1056/nejmoa1701067
8. Moreno R., Mehta S.R. Nonculprit vessel intervention: let’s COMPLETE the evidence. Rev. Esp. Cardiol. (English Ed). 2017; 70(6): 418–420. DOI: 10.1016/j.rec.2016.12.029
9. Bangalore S., Toklu B., Wetterslev J. Complete versus culprit-only revascularization for ST-segment-elevation myocardial infarction and multivessel disease: a meta-analysis and trial sequential analysis of randomized trials. Circ. Cardiovasc. Interv. 2015; 8(4): e002142. DOI: 10.1161/circinterventions.114.002142
10. Elgendy I.Y., Mahmoud A.N., Kumbhani D.J., Bhatt D.L., Bavry A.A. Complete or culprit-only revascularization patients with multivessel coronary artery disease undergoing percutaneous coronary intervention for: a pairwise and network meta-analysis of randomized trials. JACC Cardiovasc. Interv. 2017; 10(4): 315–324. DOI: 10.1016/j.jcin.2016.11.047
11. Akin I., Schneider H., Ince H., Kische S., Rehders T.C., Chatterjee T., Nienaber C.A. Second- and third-generation drug-eluting coronary stents: progress and safety. Hertz. 2011; 36(3): 190–197. DOI: 10.1007/s00059-011-3458-z
12. Kalugina L.S. Urvantseva I.A. Myocardial revascularization in patients with multivessel coronary lesions. Patologiya Krovoobrashcheniya i Kardiokhirurgiya. 2016; 20(3): 14–19 (In Russ., English abstract). DOI: 10.21688/1681-3472-2016-3-14-19
13. Ibanez B., James S., Agewall S., Antunes M.J., Bucciarelli-Ducci Ch., Bueno H., Caforio A.L.P., Crea F., Goudevenos J.A., Halvorsen S., Hidrucks G., Kastrati A., Lenzen M.J., Prescott E., Roff M., Valdimigli M., Varenhorst Ch., Vranckx P., Widimsky P. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2018; 39(2): 119–177. DOI: 10.1093/eurheartj/ehx393
14. Hillis L.D., Smith P.K., Anderson J.L., et al. 2011ACCF/ AHA Guidline for Coronary Artery Bypass Graft Surgery. A report of the American Coolege of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons. J. Am. Coll. Cardiol. 2011; 58(24): e123–210. DOI: 10.1016/j.jacc.2011.08.009
15. Food and Drug Administration (FDA) (2016) Non-Inferioty Clinical Trials to Establish Effectiveness. Guidance for Industry. URL: https://www.fda.gov/downloads/Drugs/Guidances/UCM202140.pdf (дата обращения: 20.11.2018).
16. Serruys P.W., Morice M.-C., Kappetein А.P., Colombo A., Holmes D.R., Mack M.J., Stahle E., Feldman T.E., van den Brand M., Bass E.J., Van Dyck N., Leadley K., Dawkins K.D., Mohr F.W. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N. Engl.J. Med. 2009; 360: 961–972. DOI: 10.1056/NEJMoa0804626
17. Mohr F.W., Morice M.C., Kappetein A.P., Feldman T.E., Ståhle E., Colombo A., Mack M.J., Holmes D.R. Jr, Morel M.A., Van Dyck N., Houle V.M., Dawkins K.D., Serruys P.W. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013; 381(9867): 629–638. DOI: 10.1016/S0140-6736(13)60141-5
18. Park S.J., Kim Y.H., Park D.W., Yun S.C., Ahn J.M., Song H.G., Lee J.Y., Kim W.J., Kang S.J., Lee S.W., Lee C.W., Park S.W., Chung C.H., Lee J.W., Lim D.S., Rha S.W., Lee S.G., Gwon H.C., Kim H.S., Chae I.H., Jang Y., Jeong M.H., Tahk S.J., Seung K.B. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N. Engl.J. Med. 2011; 364(18): 1718–1727. DOI: 10.1056/nejmoa11000452
19. Yagafarov I.R., Tenin E.V., Sibagatullin N.G., Zakirov I.R., Yagafarova L.F., Khatypov M.G., Bikchantaev A.A. Optimizing cardioplegia in cardiopulmonary bypass surgeries. Kazanskii Meditsinskii Zhurnal. 2015; 96(3): 330–334 (In Russ., English abstract).
20. Boudriot E., Thiele H., Walther T., Liebetrau C., Boeckstegers P., Pohl T., Reichart B., Mudra H., Beier F., Gansera B., Neumann F.J., Gick M., Zietak T., Desch S., Schuler G., Mohr F.W. Randomized comparison of percutaneous coronary intervention with sirolimus-eluting stents versus coronary artery bypass grafting in unprotected left main stem stenosis. J. Am. Coll. Cardiol. 2011; 57(5): 538–545. DOI: 10.1016/j.jacc.2010.09.038
Review
For citations:
Bocharov A.V., Popov L.V. RESULTS OF STAGED ENDOVASCULAR MYOCARDIAL REVASCULARISATION IN PATIENTS TREATED FOR ACUTE CORONARY SYNDROME WITH ST-SEGMENT ELEVATION AND MULTIVESSEL DISEASE. Kuban Scientific Medical Bulletin. 2019;26(3):25-32. (In Russ.) https://doi.org/10.25207/1608-6228-2019-26-3-00-25-32
Views:
469
Email this article 